129 related articles for article (PubMed ID: 10533157)
1. Double-blind, placebo-controlled study of the effects of tibolone on bone mineral density in postmenopausal osteoporotic women with and without previous fractures.
Pavlov PW; Ginsburg J; Kicovic PM; van der Schaaf DB; Prelevic G; Bennink HJ
Gynecol Endocrinol; 1999 Aug; 13(4):230-7. PubMed ID: 10533157
[TBL] [Abstract][Full Text] [Related]
2. Association of tibolone and fluoride displays a pronounced effect on bone mineral density in postmenopausal osteoporotic women.
Reginster JY; Agnusdei D; Gennari C; Kicovic PM
Gynecol Endocrinol; 1999 Oct; 13(5):361-8. PubMed ID: 10599554
[TBL] [Abstract][Full Text] [Related]
3. [Postmenopausal hormonal treatment: conventional hormone replacement therapy or tibolone? Effects on bone].
Reginster JY
J Gynecol Obstet Biol Reprod (Paris); 2002 Oct; 31(6):541-9. PubMed ID: 12407324
[TBL] [Abstract][Full Text] [Related]
4. A randomized study of tibolone on bone mineral density in osteoporotic postmenopausal women with previous fractures.
Studd J; Arnala I; Kicovic PM; Zamblera D; Kröger H; Holland N
Obstet Gynecol; 1998 Oct; 92(4 Pt 1):574-9. PubMed ID: 9764631
[TBL] [Abstract][Full Text] [Related]
5. Effects of 8 years of treatment with tibolone 2.5 mg daily on postmenopausal bone loss.
Rymer J; Robinson J; Fogelman I
Osteoporos Int; 2001; 12(6):478-83. PubMed ID: 11446564
[TBL] [Abstract][Full Text] [Related]
6. [The effect of a one-year alendronate therapy on postmenopausal osteoporosis. (Results in Hungary of an international multicenter clinical study)].
Bettembuk P; Balogh A
Orv Hetil; 1999 Dec; 140(50):2799-803. PubMed ID: 10647267
[TBL] [Abstract][Full Text] [Related]
7. Prevention of bone loss by clodronate in early postmenopausal women with vertebral osteopenia: a dose-finding study.
Välimäki MJ; Laitinen K; Patronen A; Puolijoki H; Seppänen J; Pylkkänen L; Aranko SM; Sairanen S; Blåfield H; Rekiaro M; Väisänen K; Kormano M; Mäkinen L; Salmi J; Ala-Kaila K; Perttilä J; Vesterinen K; Koivunoro K;
Osteoporos Int; 2002 Dec; 13(12):937-47. PubMed ID: 12459936
[TBL] [Abstract][Full Text] [Related]
8. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis.
Neer RM; Arnaud CD; Zanchetta JR; Prince R; Gaich GA; Reginster JY; Hodsman AB; Eriksen EF; Ish-Shalom S; Genant HK; Wang O; Mitlak BH
N Engl J Med; 2001 May; 344(19):1434-41. PubMed ID: 11346808
[TBL] [Abstract][Full Text] [Related]
9. Growth hormone increases bone mineral content in postmenopausal osteoporosis: a randomized placebo-controlled trial.
Landin-Wilhelmsen K; Nilsson A; Bosaeus I; Bengtsson BA
J Bone Miner Res; 2003 Mar; 18(3):393-405. PubMed ID: 12619921
[TBL] [Abstract][Full Text] [Related]
10. Prevention of bone loss with tibolone in postmenopausal women: results of two randomized, double-blind, placebo-controlled, dose-finding studies.
Gallagher JC; Baylink DJ; Freeman R; McClung M
J Clin Endocrinol Metab; 2001 Oct; 86(10):4717-26. PubMed ID: 11600531
[TBL] [Abstract][Full Text] [Related]
11. Prevention of postmenopausal bone loss at lumbar spine and upper femur with tibolone: a two-year randomised controlled trial.
Beardsworth SA; Kearney CE; Purdie DW
Br J Obstet Gynaecol; 1999 Jul; 106(7):678-83. PubMed ID: 10428524
[TBL] [Abstract][Full Text] [Related]
12. Tibolone: prevention of bone loss in late postmenopausal women.
Bjarnason NH; Bjarnason K; Haarbo J; Rosenquist C; Christiansen C
J Clin Endocrinol Metab; 1996 Jul; 81(7):2419-22. PubMed ID: 8675554
[TBL] [Abstract][Full Text] [Related]
13. Effects of two doses of tibolone on trabecular and cortical bone loss in early postmenopausal women: a two-year randomized, placebo-controlled study.
Berning B; Kuijk CV; Kuiper JW; Bennink HJ; Kicovic PM; Fauser BC
Bone; 1996 Oct; 19(4):395-9. PubMed ID: 8894146
[TBL] [Abstract][Full Text] [Related]
14. A 3-year study of prevention of postmenopausal bone loss: conjugated equine estrogens plus medroxyprogesterone acetate versus tibolone.
Thiébaud D; Bigler JM; Renteria S; Pache T; Welti HJ; Landry M; Burckhardt P
Climacteric; 1998 Sep; 1(3):202-10. PubMed ID: 11907945
[TBL] [Abstract][Full Text] [Related]
15. Randomized, double-masked, 2-year comparison of tibolone with 17beta-estradiol and norethindrone acetate in preventing postmenopausal bone loss.
Roux C; Pelissier C; Fechtenbaum J; Loiseau-Peres S; Benhamou CL
Osteoporos Int; 2002 Mar; 13(3):241-8. PubMed ID: 11991445
[TBL] [Abstract][Full Text] [Related]
16. Urinary bone resorption markers in monitoring treatment of symptomatic osteoporosis.
Parviainen MT; Jääskeläinen K; Kröger H; Arnala I; Alhava E
Clin Chim Acta; 1999 Jan; 279(1-2):145-54. PubMed ID: 10064126
[TBL] [Abstract][Full Text] [Related]
17. Comparative effects on bone mineral density of tibolone, transdermal estrogen and oral estrogen/progestogen therapy in postmenopausal women.
Prelevic GM; Bartram C; Wood J; Okolo S; Ginsburg J
Gynecol Endocrinol; 1996 Dec; 10(6):413-20. PubMed ID: 9032569
[TBL] [Abstract][Full Text] [Related]
18. The influence of physical activity on the response of bone mineral density to 5 years tibolone.
Brooke-Wavell K; Prelevic GM; Bartram C; Ginsburg J
Maturitas; 2000 Jun; 35(3):229-35. PubMed ID: 10936739
[TBL] [Abstract][Full Text] [Related]
19. Nandrolone decanoate and intranasal calcitonin as therapy in established osteoporosis.
Flicker L; Hopper JL; Larkins RG; Lichtenstein M; Buirski G; Wark JD
Osteoporos Int; 1997; 7(1):29-35. PubMed ID: 9102059
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of conjugated estrogen plus medroxyprogesterone acetate versus tibolone in early postmenopausal Chinese women.
Yang TS; Tsan SH; Chen CR; Chang SP; Yuan CC
Zhonghua Yi Xue Za Zhi (Taipei); 1999 May; 62(5):308-15. PubMed ID: 10389286
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
